Open Access

Risk factors for bronchiolitis hospitalization during the first year of life in a multicenter Italian birth cohort

  • Marcello Lanari1,
  • Federica Prinelli2, 3,
  • Fulvio Adorni2,
  • Simona Di Santo4,
  • Silvia Vandini5Email author,
  • Michela Silvestri6,
  • Massimo Musicco2, 4 and
  • and the Study Group of Italian Society of Neonatology on Risk Factors for RSV Hospitalization
Italian Journal of Pediatrics201541:40

DOI: 10.1186/s13052-015-0149-z

Received: 2 February 2015

Accepted: 18 May 2015

Published: 26 May 2015

Abstract

Background

Respiratory Syncytial Virus (RSV) is one of the main causes of respiratory infections during the first year of life. Very premature infants may contract more severe diseases and ‘late preterm infants’ may also be more susceptible to the infection.

The aim of this study is to evaluate the risk factors for hospitalization during the first year of life in children born at different gestational ages in Italy.

Methods

A cohort of 33-34 weeks gestational age (wGA) newborns matched by sex and age with two cohort of newborns born at 35-37 wGA and > 37 wGA were enrolled in this study for a three-year period (2009-2012).

Hospitalization for bronchiolitis (ICD-9 code 466.1) during the first year of life was assessed through phone interview at the end of the RSV season (November–March) and at the completion of the first year of life.

Results

The study enrolled 2314 newborns, of which 2210 (95.5 %) had a one year follow-up and were included in the analysis; 120 (5.4 %) were hospitalized during the first year of life for bronchiolitis. Children born at 33-34 wGA had a higher hospitalization rate compared to the two other groups. The multivariate analysis carried out on the entire population associated the following factors with higher rates for bronchiolitis hospitalization: male gender; prenatal treatment with corticosteroids; prenatal exposure to maternal smoking; singleton delivery; respiratory diseases in neonatal period; surfactant therapy; lack of breastfeeding; siblings <10 years old; living in crowded conditions and/or in unhealthy households and early exposure to the epidemic RSV season. When analysis was restricted to preterms born at 33-34 wGA the following variables were associated to higher rates of bronchiolitis hospitalization: male gender, prenatal exposure to maternal smoking, neonatal surfactant therapy, having siblings <10 years old, living in crowded conditions and being exposed to epidemic season during the first three months of life.

Conclusion

Our study identified some prenatal, perinatal and postnatal conditions proving to be relevant and independent risk factors for hospitalization for bronchiolitis during the first year of life. The combination of these factors may lead to consider palivizumab prophylaxis in Italy.

Key words

Bronchiolitis Hospitalization Risk factor Respiratory syncytial virus Prophylaxis Palivizumab Children

Background

Bronchiolitis is the first cause of hospitalization of infants in the USA and it is the most frequent lower respiratory tract disease in preterm infants [14].

Infants with chronic lung disease (CLD), congenital heart disease (CHD), immunodeficiency and neuromuscular disorders are particularly at high risk of hospitalization for bronchiolitis [5]. Moreover, preterm infants [6] are also more prone to these infections due to the impaired development of the lung and of the immune system. In particular, it has been observed that prematurity has been associated to an increased likelihood of hospitalization for RSV bronchiolitis [1].

Studies performed in Europe and in the USA have also shown that infants born between 33 and 35 wGA have a higher risk of hospitalization due to RSV infections than full-term infants [1, 7, 8]. This population is at risk of developing severe RSV infection that can result in morbidity and yield similar expenditures to infants born before 33 wGA [1, 9, 10]. Several studies have found other determinants of bronchiolitis and in particular of severe diseases caused by RSV [11], however, two of the largest studies carried out on cohort of infants born at these gestational ages [1214] reported inconclusive results, probably due to the methodologic approach and differences in context (i.e.social, epidemic, climatic) [8].

In Italy, a multicenter study enrolling over 1200 children younger than two years hospitalized for lower respiratory tract infections (LRTI) found that two-thirds of hospitalizations occurred in children with low birth weight and low gestational age, with an incidence 8.5 % in infants born before 36 weeks vs. 4 % in the general population [15]. Moreover, among children with bronchiolitis, RSV infection was particularly frequent in those born at lower gestational age. Among the patients who were RSV-positive, 60.0 % were born at a gestational age of 33 weeks; 59.1 % between 34–35 wGA; and 47.4 % at more than 35 wGA [15]. This study found that passive tobacco smoke exposure increased the rate of hospitalization for RSV infections (RR 1.4). Moreover, RSV positivity was related to birth order, since it was higher in infants with a larger number of siblings [15].

The aim of the current study is to evaluate the role of prenatal, perinatal and postnatal conditions in determining the risk of hospitalization for bronchiolitis in a large cohort of preterm with GA 33 weeks or more and full term newborns.

In addition to that, the analysis of risk factors was focused on preterm infants born at 33-34 wGA. This population of preterm infants, although well documented to be at high risk of severe RSV infections [1, 7, 8] has been recently crossed out from the revised AAP guidelines [16] for prophylaxis with palivizumab, a monoclonal humanized antibody neutralizing RSV. Two important studies [1214] analyzed the risk factors for hospitalization in these preterm infants; however, the analysis of risk factors in a large Italian birth cohort has not yet been performed. The determination of national risk factors could improve the capacity to detect newborns at particularly high risk for severe respiratory infection and hospitalization that may be considered for a “tailored” prophylaxis treatment. In Italy prophylaxis with palivizumab is regulated by the Italian Neonatology Society guidelines [17], but they are widely disregarded especially in preterm infants born at 33 wGA or more. The Italian Neonatology Society is reviewing these recommendations through the update of the epidemiological data.

The results of the present multicenter study and the analysis of the risk factors will be considered by the Italian Neonatology Society for the update of the guidelines.

Methods

This is a multicenter cohort study including consecutive newborns born between 2009 and 2012. All subjects were enrolled at birth and followed up for the first year of life.

Thirty Neonatology Units from hospitals with 1000 or more deliveries per year located in the northern, central, southern and insular regions of Italy participated in this study. Ethic Committees of each participating hospital approved the study protocol. A written consent was obtained from legal guardians of all patients.

For each enrolled newborn of 33-34 wGA, two further newborns of the same sex and with the nearest date of birth were enrolled: one of 35-37 wGA and one of >37 wGA.

Exclusion criteria were life expectancy shorter than six months; haemodynamically significant congenital heart diseases and chronic lung diseases (defined as oxygen requiring at 28 days of life [18]); concurrent enrolment in another trial; programmed or administered RSV prophylaxis with palivizumab and inability to follow up at our center during the study period.

In each center, the enrolling physician filled out a record with prenatal and perinatal data after checking inclusion and exclusion criteria, within two days after the births.

In order to detect possible occurrence of respiratory infections (leading to hospitalization or not), after enrolment a structured phone interview was carried out twice with the parents by a trained interviewer from the Italian National Research Council (CNR). The first interview was carried out at the end of the epidemic RSV season (at end of March in Italy [19]) and the second one at 12 months of age. During the phone interview, postnatal data on potential risk factors such as lack of breastfeeding, exposure to environmental pollution and/or to passive cigarette smoke were recorded.

When parents reported hospitalization of the child for any cause, the enrolling physician collected all the relevant clinical and therapeutic information from the hospital clinical record forms.

The primary outcome was the occurrence of hospitalization/death for bronchiolitis during the first year of life. Hospitalizations for bronchiolitis were defined according to the hospital discharge form with the ICD-9 codes 466.1 (acute bronchiolitis).

Table 1 reports the variables registered by the enrolling physicians and from the interviews concerning neonatal, perinatal and postnatal variables potentially associated to bronchiolitis.
Table 1

Baseline demographic and clinical characteristic of the enrolled newborns and of their parents: prenatal conditions

 

wGA groups

 

33+0d-34+6d (No. 737)

35+0d-37+6d (No. 767)

≥38+0d (No. 706)

Total (No. 2210)

Pregnancy

    

Assisted reproductive technique

154 (20.9)

90 (11.7)

7 (1.0)

251 (11.4)

Intrauterine growth restriction (IUGR)

82 (11.1)

58 (7.6)

7 (1.0)

147 (6.7)

Mother’s characteristics

    

Age >40 year

95 (12.9)

91 (11.9)

46 (6.5)

232 (10.5)

Low education

185 (25.1)

184 (24)

131 (18.6)

500 (22.6)

Nationality

    

  Italian

654 (88.7)

703 (91.7)

655 (92.8)

2012 (91.0)

  African

12 (1.6)

9 (1.2)

8 (1.1)

29 (1.3)

  Asian

10 (1.4)

2 (0.3)

6 (0.8)

18 (0.8)

  Eastern Europe

36 (4.9)

37 (4.8)

22 (3.1)

95 (4.3)

  Western Europe

13 (1.8)

4 (0.5)

7 (1.0)

24 (1.1)

Southern America

12 (1.6)

12 (1.6)

8 (1.1)

32 (1.4)

Maternal diseases during pregnancy

275 (37.3)

220 (28.7)

92 (13.0)

587 (26.6)

Treatment with corticosteroids

404 (54.8)

157 (20.5)

4 (0.6)

565 (25.6)

History of respiratory diseases

138 (18.7)

134 (17.5)

132 (18.7)

404 (18.3)

  Asthma

49 (6.6)

50 (6.5)

47 (6.7)

146 (6.6)

  COPD

12 (1.6)

8 (1.0)

6 (0.8)

26 (1.2)

  Eczema

33 (4.5)

28 (3.7)

26 (3.7)

87 (3.9)

  Rhinitis

78 (10.6)

82 (10.7)

90 (12.7)

250 (11.3)

  Wheezing

1 (0.1)

-

1 (0.1)

2 (0.1)

Prenatal smoke exposure

    

  None

559 (75.8)

560 (73.0)

525 (74.4)

1644 (74.4)

  To maternal active smoking only

76 (10.3)

93 (12.1)

61 (8.6)

230 (10.4)

  To maternal passive smoking only

102 (13.8)

114 (14.9)

120 (17.0)

336 (15.2)

Father’s characteristics

    

Age >40 year

184 (25.0)

203 (26.5)

158 (22.4)

545 (24.7)

Low education

219 (29.7)

261 (34.0)

198 (28.0)

678 (30.7)

History of respiratory diseases

138 (18.7)

158 (20.6)

141 (20.0)

437 (19.8)

  Asthma

51 (6.9)

48 (6.3)

48 (6.8)

147 (6.7)

  COPD

8 (1.1)

14 (1.8)

8 (1.1)

30 (1.4)

  Eczema

15 (2.0)

12 (1.6)

15 (2.1)

42 (1.9)

  Rhinitis

100 (13.6)

133 (17.3)

117 (16.6)

350 (15.8)

All data are reported as No. (%).wGA = weeks of gestational age; yrs = years

Low level of parental education was defined as no education or primary education (vs. secondary or higher).

Presence of maternal diseases during pregnancy was identified when the mother suffered from chronic conditions or other disorders affecting the pregnancy outcome such as hypertension, preeclampsia or diabetes mellitus.

The presence of parental asthma, COPD and wheezing was recorded when the parents reported to have previously received the diagnosis by other physicians.

A baby was considered small for gestational age (SGA) if smaller than normal for the gestational age, most commonly defined as a weight below the 10th percentile for gestational age, according to the Italian neonatal anthropometric charts [20].

The presence of siblings in the household of the child was defined as ≥1 sibling younger than 10 years living ≥3 days per week in the same house. A crowded living condition was defined as ≥ 5 inhabitants per household excluding the study subject and his/her siblings less than 10 years old.

Breastfeeding was evaluated combining the information collected at hospital discharge and that derived from the two follow up interviews, and was defined as feeding with maternal milk (exclusively or associated with formula), either from breast or bottle. Children were first classified as ‘never breastfed’ or ‘ever breastfed’, and children ‘ever breastfed’ were further classified according to having been fed exclusively with maternal milk or with both maternal milk and formula together.

Pollution exposure (i.e. residence in the proximity of intense traffic areas) and indoor humidity exposure (i.e. visible mold growth) were registered according to interviews. Exposure to epidemic season was defined as living for at least one month of their first three months of life from November to March.

Sample size was calculated by fixing a predefined precision of the estimate of the absolute risk of hospitalization and/or death for RSV-induced or non RSV-induced bronchiolitis during the first year of life. Assuming that the risk of hospitalization for bronchiolitis during the first year of life was about 7 %, a sample size of 2500 newborns could provide a 95 % confidence interval (95%CI) of 6.0 to 8.1 % that is largely consistent with a random error of less than 20 %.

The probability of bronchiolitis-related hospitalization was considered as a time-dependent variable, and a survival analysis was carried-out using Cox proportional hazard models to calculate the cumulative time-dependent risks. Relative risks were estimated as hazard ratios and 95 % confidence limits were derived from the standard errors of the parameter estimated by the model.

Crude hazard ratios were calculated for all the considered variables. Multivariable analyses were carried-out first on all the variables grouped within each set of pre-, peri-, and post-natal risk factors. All the variables significantly associated with the risk of hospitalization for bronchiolitis in these initial multivariable analyses entered into the final regression model.

Analyses were carried out using SPSS software package version 20.0 (IBM Corporation 2010; IBM SPSS Statistics for Windows).

Results

In a three-year period, 2314 healthy newborns were enrolled. Out of those 2210 (95.5 %) of which 1150 male and 1060 female underwent a one year follow-up and were included in the analysis; 104 were lost to follow-up and were excluded. No infants died during the follow-up period.

Baseline demographic and clinical characteristics of the enrolled newborns and their parents by gestational age are reported in Tables 1, 2 and 3.
Table 2

Baseline demographic and clinical characteristic of the enrolled newborns and of their parents: perinatal/neonatal conditions

 

wGA groups

 

33+0d-34+6d (No. 737)

35+0d-37+6d (No. 767)

≥38+0d (No. 706)

Total (No. 2210)

Male gender

382 (51.8)

400 (52.2)

368 (52.1)

1150 (52.0)

Caesarean delivery

607 (82.4)

520 (67.8)

262 (37.1)

1389 (62,9)

Singleton delivery

419 (56.9)

552 (72)

702 (99.4)

1673 (75.7)

APGAR score at five minutes <8

42 (5.7)

22 (2.9)

7 (1.0)

71 (3.2)

Birth weight [g (mean, SD)]

2031 (380.9)

2605.1 (517.1)

3296.1 (423.6)

2635.1 (678.1)

Small for gestational age (SGA)

135 (18.3)

85 (11.1)

19 (2.7)

239 (10,8)

Resuscitation after birth

199 (27.0)

109 (14.2)

38 (5.4)

346 (15.7)

Neonatal hospitalization

715 (97.0)

430 (56.1)

137 (19.4)

1282 (58)

Respiratory diseases

296 (40.2)

121 (15.8)

23 (3.3)

440 (19.9)

Surfactant therapy

48 (6.5)

11 (1.4)

1 (0.1)

60 (2.7)

Antibiotics therapy

149 (20.2)

47 (6.1)

6 (0.8)

202 (9.1)

All data are reported as No. (%), unless otherwise specified; wGA = weeks of gestational age

Table 3

Baseline demographic and clinical characteristic of the enrolled newborns and of their parents: postnatal conditions

 

wGA groups

 

33+0d-34+6d (No. 737)

35+0d-37+6d (No. 767)

≥38+0d (No. 706)

Total (No. 2210)

Presence of siblings

    

  None

472 (64.0)

444 (57.9)

394 (55.8)

1310 (59.3)

  ≤ 10 year

223 (30.3)

289 (37.7)

280 (39.7)

792 (35.8)

  > 10 year

42 (5.7)

34 (4.4)

32 (4.5)

108 (4.9)

Residential crowding

88 (11.9)

86 (11.2)

53 (7.5)

227 (10.3)

Lack of breastfeeding

209 (28.4)

193 (25.2)

80 (11.3)

482 (21.8)

Pollution exposure

77 (10.4)

102 (13.3)

87 (12.3)

266 (12.0)

Exposure to parental smoking

310 (42.1)

320 (41.7)

272 (38.5)

902 (40.8)

Indoor humidity

75 (10.2)

75 (9.8)

72 (10.2)

222 (10)

Exposure to epidemic season

437 (59.3)

474 (61.8)

412 (58.4)

1323 (59.9)

Hospitalization for bronchiolitis

54 (7.3)

41 (5.3)

25 (3.5)

120 (5.4)

All data are reported as No. (%); wGA = weeks of gestational age; yrs = years

Conception through assisted reproductive technology, multiple births, mothers with diseases potentially harmful for the pregnancy, or who were treated with corticosteroids, were more frequent in the group of babies born at 33-34 wGA. The babies in this group had a lower birth weight than newborns born at a longer gestational age and were more frequently SGA. In addition, they had more frequently neonatal respiratory diseases and/or received more frequently medical interventions (neonatal resuscitation in delivery room, hospitalization in neonatal department and/or in neonatal intensive care unit, surfactant and/or antibiotic therapy).

Hospitalization for bronchiolitis during the first year of life

Out of the babies who underwent follow-up at 12 months, 120 (5.4 %) were admitted to hospital for bronchiolitis; 65/120 (54 %) hospitalizations occurred within the first 3 months of life and 90/120 (75 %) within the first 6 months of life. The majority of hospital admissions occurred during the RSV epidemic season and 95/120 (87.5 %) cases occurred in preterm infants, of whom 54/120 (45 %) were born at 33-34 wGA. The majority of the hospitalizations in this group occurred within the first 6 months (43/54, 79.6 %) of life, 31/54 (57 %) within the first 3 months of life.

Of the 120 hospitalized infants, 31/120 (26 %) were tested for RSV and 26/31 (83 %) were positive.

At univariate analysis (Table 4), the risk estimates (hazard ratios) for hospitalization for bronchiolitis increased 2 and 1.5 folds respectively for those born at 33-34 and 35-37 wGA compared to the newborns born at more than 37 wGA. Rates of bronchiolitis occurrence increased 1.6 folds for male newborns.
Table 4

Relative risks estimates (hazard ratios) according to prenatal, neonatal/perinatal and postnatal/environmental conditions for hospitalization

Exposures

Bronchiolitis hospitalization +/- exposed (%)

Multivariable HRa (95%b)

 

Events/unexposed

Events/exoposed [HRc, 95 % CI]

 

Gender-male

44/1060 (4.2)

76/1150 (6.6) [1.6, 1.1-2.3]

1.6 (1.1-2.4)

Week of gestational age

   

33-34 vs > 37

25/706 (3.5)

54/737 (7.3) [2.1, 1.3-3.4]

 

35-37 vs > 37

25/706 (3.5)

41/767 (5.3) [1.5, 0.9-2.5]

 

Prenatal

   

Mother’s history of BPCO

117/2184 (5.4)

3/26 (11.5) [2.2, 0.7–6.9]

 

Mother’s history of eczema

113/2123 (5.3)

7/87 (8.0) [1.6, 0.7–3.4]

 

Father’s history of BPCO

115/2180 (5.3)

5/30 (16.7) [3.6, 1.5–8.9]

 

Assisted reproductive technology

115/1959 (5.9)

5/251 (2.0) [0.3, 0.1–0.6]

 

Treatment with corticosteroids

75/1645 (4.6)

45/565 (8.0) [1.4, 0.9–2.2]

1.6 (1.1–2.4)

Mother’s pregnancy pathologies

78/1623 (4.8)

42/587 (7.2) [1.4, 0.9–2.0]

 

Prenatal smoke exposure

58/1358 (4.3)

62/852 (7.3) [1.8, 1.2–2.5]

1.6 (1.1–2.3)

Neonatal/Perinatal

   

Delivery

   

Singleton

23/537 (4.3)

97/1673 (5.8) [1.9, 1.2–3.0]

1.8 (1.1–2.9)

Resuscitation with O2

95/1911 (5.0)

25/299 (8.4) [1.4, 0.9–2.3)]

 

Perinatal

   

Neonatal hospitalization

83/1770 (4.7)

37/440 (8.4) [1.5, 1.0–2.2]

1.6 (1.0–2.5)

Surfactant therapy

109/2150 (5.1)

11/60 (18.3) [3.8, 1.6–5.8]

2.0 (1.1–3.8)

Postnatal (environmental)

   

Having siblings < 10 years

40/1310 (3.1)

73/792 (9.2) [3.3, 2.2–4.8]

3.0 (2.0–4.5)

       ≥ 10 years

40/1310 (3.1)

7/108 (6.5) [2.2, 1.0–5.0]

1.9 (0.9–4.4)

Environmental (home) conditions

   

Residential crowding

93/1983 (4.7)

27/227 (11.9) [2.6, 1.7–3.9]

2.4 (1.5–3.7)

Indoor humidity

101/1988 (5.1)

19/222 (8.6) [1.7, 1.0–2.8]

1.6 (1.0–2.6)

Heating system generating smoke

90/1742 (5.2)

30/468 (6.4) [1.2, 0.8–1.8]

 

Residence in the proximity of intense vehicular traffic roads

100/1926 (5.2)

20/284 (7.0) [1.4, 0.9–2.3]

 

Sibilings

63/1414 (4.5)

57/796 (7.2) [1.6, 1.1–2.3]

 

Lack of breastfeeding

78/1728 (4.5)

42/482 (8.7) [1.8, 1.2-2.6]

1.8 (1.2-2.6)

Passive cigarette smoke exposure

112/2102 (5.3)

8/108 (7.4) [1.5, 0.7–3.1]

 

Exposed to epidemic RSV season

31/887 (3.5)

89/1323 (6.7) [2.0, 1.3–3.0]

1.9 (1.3–2.9)

aEstimates from a model including all significant variables at gender and weeks of gestational age adjusted analysis

b95 % Confidence Interval

cHazard ratios estimates adjusted for gender and weeks of gestational age

The prenatal, neonatal and postnatal conditions found to be significant at univariate analysis were included in the multivariate analysis (Table 4 and 5).
Table 5

Relative risks estimates (hazard ratios) of hospitalization for bronchiolitis in 33+0d-34+6d wGA newborns

 

Crude HR (95 % CI)

Adjusted HR (95 % CI)

  Prenatal Conditions

  

Assisted reproductive technology

0.3 (0.1-0.8)

 

Prenatal smoke exposure

1.9 (1.1-3.3)

2.0 (1.2-3.5)

  Neonatal Conditions

  

Male gender

1.6 (1.1-2.3)

1.6 (1.0-2.7)

Singleton

1.7 (1.1-3.0)

 

Apgar in the first 5 min <8

2.2 (1.1-4.9)

 

Birth weight in g

1.0 (1.0-1.0)

 

Surfactant therapy

3.8 (2.0-7.4)

3.1 (1.6-6.0)

Antibiotic therapy

2.0 (1.1-3.5)

 

  Postnatal Conditions

  

Presence of siblings ≤10 year

3.8 (2.1-6.6)

3.2 (1.8-5.7)

Residential crowding

3.0 (1.7-5.5)

2.9 (1.6-5.4)

Indoor humidity

1.9 (1.1-3.8)

 

Exposure to epidemic season

1.8 (1.0-3.0)

1.8 (1.0-3.3)

wGA = weeks of gestational age; HR = hazard risk; 95 %CI = 95 % confidence interval; yrs = years

At univariate analysis, the prenatal conditions that significantly increased the risk of hospitalization for bronchiolitis were: father history of COPD and prenatal exposure of the mother to active or passive smoking. Mother’s comorbid conditions (i.e. diabetes, hypertension) and treatment with corticosteroids showed an increased risk near statistical significance and were included in the multivariable analyses. Among the neonatal/perinatal risk factors, singleton delivery, respiratory diseases, surfactant therapy and lack of breastfeeding were associated to significantly higher risks of bronchiolitis admission at univariate analysis. Resuscitation with O2 at birth was associated with a 1.4 fold increased risk but reached only borderline statistical significance and was retained for subsequent analyses.

With regard to postnatal/environmental conditions, having siblings younger than 10 years, crowded living environment and being exposed to epidemic RSV season were associated with significantly higher rates of hospitalization. Residence in proximity of intense vehicular traffic determined a borderline statistically significant increase of risk for hospitalization for bronchiolitis and was retained for further multivariable analyses.

On multivariate analysis, a significant increase of the risk of hospitalization for bronchiolitis in the entire cohort was associated to male gender; prenatal treatment with corticosteroids; tobacco smoke exposure during pregnancy; singleton delivery; respiratory disorders and administration of surfactant at birth, lack of breastfeeding; siblings younger than 10 years; crowded living conditions and exposure to household humidity and exposure to epidemic season (Table 4).

Subgroup analysis on the group of preterm born at 33-34 wGA revealed that the significant risk factors partially differ from the results of the analysis performed on the entire group. At univariate analysis in this particular group, the significant risk factors for hospitalization for bronchiolitis are summarized in Table 5. At multivariate analysis only six factors maintained statistical significance: male gender; prenatal exposure to maternal smoking; neonatal surfactant therapy; having siblings younger than 10 years old, living in crowded conditions and exposure to epidemic RSV season (Table 5).

Discussion

This study on infants born at 33 wGA or more provides an updated report on hospitalizations for bronchiolitis within an Italian network of thirty Neonatology and Pediatric Units in a large longitudinal birth cohort. When analyzing the entire cohort, we found that about 5 % of the newborns were admitted to hospital for bronchiolitis during their first year of life as well as preterm infants born at 33-34 wGA had a higher risk of hospitalization compared to those born at ≥35wGA. The criteria for hospitalization in Italy were previously proposed by several pediatric scientific society and have been summarized in an inter-society consensus document in 2014 [21]. The indications to hospitalization include clinical evaluation and analysis of pre-existing risk factors such as prematurity, congenital heart diseases or chronic diseases. Given the presence of shared national guidelines, the decision to hospitalize an infant to be derived from the analysis of all the individual criteria. Male gender, prenatal conditions (treatment with corticosteroids and exposure to tobacco smoking), neonatal conditions (singleton delivery, respiratory diseases, surfactant therapy) and environmental/postnatal conditions (lack of breastfeeding, having siblings <10 years old, crowded and unhealthy living conditions and being exposed to epidemic RSV season) were associated with a significant increase of hospitalization rate for bronchiolitis in the entire birth cohort.

The same analysis repeated in the group of infants born at 33-34 wGA proved that prenatal smoke exposure, male gender, surfactant therapy, presence of siblings < 10 years, crowded living conditions and exposure to epidemic RSV season are statistically significant risk factors for hospitalization for bronchiolitis.

The results of our analyses were adjusted for wGA, when referring to the whole cohort, or restricted to 33-34 wGA infants. According to this, our results point out that, beyond to postnatal exposures (independent from wGA), pre- and peri-natal risk factors are associated to conditions of clinical severity differently prevalent in premature or non-premature infants, so that prematurity “per se” is not to be considered a predictor.

Although severe diseases are more common among children with prematurity, CLD, CHD and other pathologic conditions, more than half of babies hospitalized for RSV infections during the first year of life [1] and 80 % of RSV-related deaths occur among children who do not have an underlying clinical high-risk condition [4, 22]. This suggests that environmental or other conditions enforce the risk condition due to prematurity and pre-existing diseases, determining an additional increase of the risk [23, 24, 10].

Our results only partially agree with other studies. These disagreements seem intrinsic to the nature of cohort studies, moreover when carried out in different settings and with different methodologies. We can hypothesize that study procedures, different populations, data collection, variable definitions and follow-up duration may have played a role in determining partially different results.

Male sex is known to be a risk factor for severe RSV bronchiolitis [23, 14] with a risk ratio of boys to girls being 1.425:1 [23].

It is also well known that smoking in pregnancy is associated with reduced lung function of the newborn [2527]. In a large case–control study from Denmark [28] that was designed to evaluate risk factors for RSV hospitalization in infants younger than 2 years, prenatal exposure to smoking was one of the significant factors on multivariate analysis (odds ratio: 1.56; 95 % CI: 1.32–1.98).

In our study, prenatal corticosteroid administration and singleton birth were observed to increase the risk for hospitalization for bronchiolitis. These data are discordant with previous studies and require further confirmation [29, 30].

A perinatal/neonatal history of respiratory diseases was observed to be a risk factor for hospitalization, since any condition impairing the early postnatal development of the lung predisposes infants to an increased risk of severe bronchiolitis.

Different papers reported conflicting results about the protective role of breastfeeding on lower respiratory infections. A preliminary analysis conducted on this birth cohort study reported a clear significant reduction of the risk of hospitalization for bronchiolitis associated with breastfeeding (exclusive or in addition to formula milk) [31], confirmed by the analysis performed in the present paper on the entire cohort. The studies by Holberg et al. [32] and Bulkow et al. [33] also described a decreased risk of RSV hospitalization in breastfeeding infants.

Both crowded living conditions and presence of siblings appear to be important risk factors for more severe acute respiratory infections. Reasons include the increased likelihood of exposure to the virus circulation and subsequently the increased risk for infection. In the Canadian PICNIC study [14], the presence of preschool-aged siblings was significantly and independently associated with an increased risk for RSV related hospitalization, and a weaker association was found with the presence of school-aged siblings. Crowded living conditions, defined as 5 or more people living in one household, was also demonstrated to be a significant risk factor for RSV related hospitalization. In some contrast, the Spanish FLIP study [13] revealed that only school-aged siblings and the presence of more than four additional residents and visitors at home were risk factors significantly associated with RSV related hospitalization. In the FLIP-2 study [12], the effect of school-aged siblings was confirmed, however crowded living conditions, identified by the same definition, was not. The Munich RSV Study Group [7], found that siblings at day care attendance significantly augmented the risk for RSV related hospitalization (OR: 3.9; 95 % CI: 1.9-8.3).

Young age at the beginning of the RSV season is a risk factor for both the development of LRTI as well as hospitalization due to RSV infection. A review of studies of RSV hospitalization rates [23] revealed that approximately 10 % to 28 % of infants hospitalized with RSV are aged below 6 weeks, 49 % to 70 % below 6 months, and 66 % to 100 % below one year.

Moreover, a recent study [34] analyzing hospitalizations for acute respiratory infections in infants < 24 months reported that the hospitalization rate was higher during the first three months of life and then consistently declined.

The greatest risk factor for hospitalization due to RSV infection appears to be the first few months of life when coincided with the first half of the RSV season. This data was also confirmed by two Spanish studies from the IRIS Group [12, 13] showing that infants with a chronological age below 10 weeks at the onset of the RSV season were at higher risk for RSV related hospitalization. In addition, the majority of hospitalization in our cohort occurred during the first 6 months of life and this result was confirmed focusing the attention in the subgroup of infants born at 33-34 wGA.

This study has some limitations. Firstly, microbiological data to confirm the presence of RSV was available only in 26 % of the cases of hospitalized infants, nevertheless with a percentage of RSV positivity higher than 80 %. Previous Italian data [19] are similar to our data (near 15 % of observed clinical bronchiolitis in hospitalized infants were negative when was tested for RSV).

Moreover, a large Italian study conducted on infants < 2 years hospitalized for LRTI [15] reported that 40.6 % of tested infants were RSV positive and the majority of RSV bronchiolitis occurred in infants ≤ 3 months.

These data suggest that the rate of etiologic misclassification can be considered low, also because of the age of our study subjects being younger than one year, at which 72-84 % of cases of bronchiolitis are RSV positive [35].

In addition, a previous study in the UK estimated that around 75 % of unspecified bronchiolitis admissions were RSV related [36]. Globally, it is estimated that only between 4 % and 28 % of children admitted with bronchiolitis are tested for RSV [3].

Considering the statistical analysis, when simultaneously analyzing several covariates, issues about overfitting, interaction and correlation may arise. Different not resolutive approaches and techniques, with relative pros and cons, may be adopted to address these issues. We think the potential overfitting was adequately controlled in our analyses by applying the multi-step selection of the variables that led to a reduced number of predictors entering the final models. Interaction is a complex issue that can be handled with different statistical techniques, none of them exhaustive, among which one of the mostly adopted is the building of mutually exclusive levels in new combined variables, as performed by Escobar et al. [37]. However, in our study no statistically significant interaction was found in the final set of predictors, so we think that the parsimonious models we proposed were appropriate for these analyses.

The strength of this study is that it is the first study to focus on a large longitudinal Italian birth cohort of newborns in order to identify rates and risk factors for hospitalization for bronchiolitis.

This could allow to improve the indications of prophylaxis with palivizumab in infants born at 33 weeks or more (particularly those born at 33-35wGA), reducing both the hospitalizations for acute bronchiolitis and its possible long-term sequelae.

Besides developing particularly serious RSV infections in the first year of life, preterm infants, even those without CLD, are at higher risk for developing recurrent wheezing, asthma [38] and allergic sensitization [3942] and have persistent abnormal lung function [43]. Moreover in a recent double-blind, placebo-controlled MAKI trial on healthy preterm infants born at a gestational age of 33 to 35 weeks, Blanken et al. [44] demonstrated that palivizumab treatment significantly reduces wheezing days during the first year of life, even after the end of treatment.

Conclusions

The analysis of local epidemiological data and risk factors involved in RSV-related hospitalization is mandatory in order to better plan preventive strategy and to develop updated national guidelines tailored for pediatric high-risk populations. Epidemiological data and a number of underlying risk factors that significantly increase the risk of severe bronchiolitis and subsequent hospitalization rate in this group of infants have been identified in our national birth cohort study, confirming that an infant’s individual characteristics and exposure to environmental factors play an important role in determining the risk of severe infection and hospitalization, independently from preterm birth.

The analysis of the weight of each risk factor could allow to define with greater accuracy the risk for bronchiolitis hospitalization for any infant during the first year of life and to take into account the prophylaxis with palivizumab through the determination of “tailored” indications.

Abbreviations

CHD: 

Congenital heart disease

CLD: 

Chronic lung disease

COPD: 

Chronic obstructive pulmonary disease

GA: 

Gestational age

LRTI: 

Lower respiratory tract infections

RSV: 

Respiratory syncytial virus

SGA: 

Small for gestational age

wGA: 

Weeks of gestational age

Declarations

Acknowledgements

We would like to acknowledge Lucy Scioscia and Filippo Filicori for editing this paper.

Study Group of Italian Society of Neonatology on Risk Factors for RSV Hospitalization”: Faldella G, Spinelli M, Corsello G, Gabriele B, La Forgia N, Loprieno S, Boldrini A, Vuerich M, Del Vecchio A, Bertino E, Fabris C, Coscia A, Fanos V, Puddu M, Gargano G, Braibanti S, Corso G, Orfeo L, De Luca MG, Paolillo P, Fabiano A, Barberi I, Arco A, Barboni G, Molinari L, Bonomi A, Ladetto L, Carlucci A, Zorzi G, Dall’Agnola A, Girardi E, Di Fabio S, Faccia P, Bottau P, Macagno F, Ellero S, Magaldi R, Rinaldi M, Memo L, Nicolini G, Ngalikpima CJ, Nosari N, Sarnelli P, Parmigiani S, Agosti M, Negri C, Corona MF, Piano F, Scarcella A, Umbaldo A, De Curtis M, Natale F, Aurilia C, Romagnoli C.

Authors’ Affiliations

(1)
Pediatrics and Neonatology Unit, Imola Hospital
(2)
Institute of Biomedical Technologies, National Research Council
(3)
Department of Food, Environmental and Nutritional Sciences, University of Milan
(4)
Foundation IRCCS Santa Lucia
(5)
Neonatology Unit S.Orsola-Malpighi Hospital
(6)
Pediatric Pulmonology and Allergy Unit, Istituto Giannina Gaslini

References

  1. Boyce TG, Mellen BG, Mitchel EF, Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infec-tion among children in medicaid. J Pediatr. 2000;137(6):865–70.PubMedView ArticleGoogle Scholar
  2. Leader S, Kohlhase K. Recent trends in severe respiratory syncytial virus (RSV) among US infants; 1997 to 2000. J Pediatr. 2003;143(5 Suppl):S127–32.PubMedView ArticleGoogle Scholar
  3. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singletoni RJ, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375(9725):1545–55.PubMed CentralPubMedView ArticleGoogle Scholar
  4. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360(6):588–98.PubMedView ArticleGoogle Scholar
  5. Thorburn K. Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus infection. Arch Dis Child. 2009;94(2):99–103.PubMedView ArticleGoogle Scholar
  6. Park HW, Lee BS, Kim AR, Yoon HS, Kim BI, Song ES, et al. Epidemiology of respiratory syncytial virus infection in infants born at less than thirty-five weeks of gestational age. Pediatr Infect Dis. 2012;31(8):99–104.View ArticleGoogle Scholar
  7. Liese JG, Grill E, Fischer B, Roeckl-Wiedmann I, Carr D, Belohradsky BH. Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany. Eur J Pediatr. 2003;162:230–6.PubMedGoogle Scholar
  8. Carbonell-Estrany X, Figueras-Aloy J, Law BJ. Infección Respiratoria Infantil por Virus Respiratorio Sincitial Study Group; Pediatric Investigators Collaborative Network on Infections in Canada Study Group. Identifying risk factors for severe respiratory syncytial virus among infants born after 33 through 35 completed weeks of gestation: different methodologies yield consistent findings. Pediatr Infect Dis J. 2004;23(11 Suppl):S193–201.PubMedView ArticleGoogle Scholar
  9. Horn SD, Smout RJ. Effect of prematurity on respiratory syn-cytial virus hospital resource use and outcomes. J Pediatr. 2003;143(5 Suppl):S133–41.PubMedView ArticleGoogle Scholar
  10. Welliver RC. Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection. J Pediatr. 2003;143(5 Suppl):S112–7.PubMedView ArticleGoogle Scholar
  11. Sommer C, Resch B, Simões EAF. Risk factors for severe respiratory syncytial virus lower respiratory tract infection. Open Microbio J. 2011;5((Suppl 2-M4):144–15.View ArticleGoogle Scholar
  12. Figueras-Aloy J, Carbonell-Estrany X, Quero-Jiménez J, et al. FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks. Pediatr Infect Dis J. 2008;27:788–93.PubMedView ArticleGoogle Scholar
  13. Figueras-Aloy J, Carbonell-Estrany X, Quero J, Group IS. Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain. Pediatr Infect Dis J. 2004;23:815–20.PubMedView ArticleGoogle Scholar
  14. Law B, Langley J, Allen U, Paes B, Lee DS, Mitchell I, et al. The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J. 2004;23:806–14.PubMedView ArticleGoogle Scholar
  15. Lanari M, Giovannini M, Giuffré L, Marini A, Rondini G, Rossi GA, et al. Prevalence of respiratory syncytial virus infection in Italian infants hospitalized for acute lower respiratory tract infections, and association between respiratory syncytial virus infection risk factors and disease severity. Ped Pulmonol. 2002;33:458–65.View ArticleGoogle Scholar
  16. American Academy of Pediatrics Committee on Infectious Diseases. American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134(2):e620–38.View ArticleGoogle Scholar
  17. Raccomandazioni della Società Italiana di Neonatologia per la prevenzione delle malattie da virus respiratorio sinciziale (VRS). Acta Neonatologica e Pediatrica 2004;18:19-30Google Scholar
  18. Baraldi E, Carraro S, Filippone M. Bronchopulmonary dysplasia: definitions and long-term respiratory outcome. Early Hum Dev. 2009;85(10 Suppl):S1–3.PubMedView ArticleGoogle Scholar
  19. Medici MC, Arcangeletti MC, Rossi GA, Lanari M, Merolla R, Paparatti UD, et al. Osservatorio VRS Study Group. Four year incidence of respiratory syncytial virus infection in infants and young children referred to emergency departments for lower respiratory tract diseases in Italy: the ‘Osservatorio VRS’ Study (2000–2004). New Microbiol. 2006;29:35–43.PubMedGoogle Scholar
  20. Bertino E, Spada E, Occhi L, Coscia A, Giuliani F, Gagliardi L, et al. Neonatal anthropometric charts: the Italian neonatal study compared with other European studies. J Pediatr Gastroenterol Nutr. 2010;51(3):353–61.PubMedGoogle Scholar
  21. Baraldi E, Lanari M, Manzoni P, Rossi GA, Vandini S, Rimini A, et al. Inter-society consensus document on treatment and prevention of bronchiolitis in newborns and infants. Ital J Pediatr. 2014;40:65.PubMed CentralPubMedView ArticleGoogle Scholar
  22. Shay DK, Holman RC, Roosevelt GE, Clarke MJ, Anderson LJ. Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children; 1979–1997. J Infect Dis. 2001;183(1):16–22.PubMedView ArticleGoogle Scholar
  23. Simoes EAF. Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease. J Pediatr. 2003;143:S118–26.PubMedView ArticleGoogle Scholar
  24. Houben ML, Bont L, Wilbrink B, Belderbos ME, Kimpen JL, Visser GH, et al. Clinical prediction rule for RSV bronchiolitis in healthy newborns: prognostic birth cohort study. Pediatrics. 2011;127(1):35–41.PubMedView ArticleGoogle Scholar
  25. Kotecha SJ, Watkins WJ, Heron J, Henderson J, Dunstan FD, Kotecha S. Spirometric lung function in school-age children. Effect of intrauterine growth retardation and catch-up growth. Am J Respir Crit Care Med. 2010;181:969–74.PubMed CentralPubMedView ArticleGoogle Scholar
  26. Leslie FM. Multigenerational epigenetic effects of nicotine on lung function. BMC Med. 2013;11:27.PubMed CentralPubMedView ArticleGoogle Scholar
  27. Joss-Moore LA, Albertine KH, Lane RH. Epigenetics and the developmental origins of lung disease. Mol Genet Metab. 2011;104(1-2):61–6.PubMed CentralPubMedView ArticleGoogle Scholar
  28. Nielsen HE, Siersma V, Andersen S, Gahrn-Hansen B, Mordhorst CH, Norgaard-Pedersen B, et al. Respiratory syncytial virus infection: risk factors for hospital admission—a case control study. Acta Paediatr. 2003;92:1314–21.PubMedView ArticleGoogle Scholar
  29. Resch B, Pasnocht A, Gusenleitner W, Müller W. Rehospitalisations for respiratory disease and respiratory syncytial virus infection in preterm infants of 29-36 weeks gestational age. J Infect. 2005;50(5):397–403.PubMedView ArticleGoogle Scholar
  30. Medlock S, Ravelli AC, Tamminga P, Mol BW, Abu-Hanna A. Prediction of mortality in very premature infants: a systematic review of prediction models. PLoS One. 2011;6(9), e23441.PubMed CentralPubMedView ArticleGoogle Scholar
  31. Lanari M, Prinelli F, Adorni F, Di Santo S, Faldella G, Silvestri M, et al. Italian Neonatology Study Group on RSV Infections. Maternal milk protects infants against bronchiolitis during the first year of life. Results from an Italian cohort of newborns. Early Hum Dev. 2013;89 Suppl 1:S51–7.PubMedView ArticleGoogle Scholar
  32. Holberg CJ, Wright AL, Martinez FD, Ray CG, Taussig LM, Lebowitz MD. Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life. Am J Epidemiol. 1991;133(11):1135–51.PubMedGoogle Scholar
  33. Bulkow LR, Singleton RJ, DeByle C, Miernyk K, Redding G, Hummel KB, et al. Risk factors for hospitalization with lower respiratory tract infections in children in rural Alaska. Pediatrics. 2012;129(5):e1220–7.PubMedView ArticleGoogle Scholar
  34. Hall CB, Weinberg GA, Blumkin AK, Edwards KM, Staat MA, Schultz AF, et al. Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. Pediatrics. 2013;132(2):e341–8.PubMedView ArticleGoogle Scholar
  35. Olabarrieta I, Gonzalez-Carrasco E, Calvo C, Pozo F, Casas I, García-García ML. Hospital admission due to respiratory viral infections in moderate preterm, late preterm and term infants during their first year of life. Allergol Immunopathol (Madr). 2014 Nov 8. doi: 10.1016/j.aller.2014.06.006.Google Scholar
  36. Muller-Pebody B, Edmunds WJ, Zambon MC, Gay NJ, Crowcroft NS. Contribution of RSV to bronchiolitis and pneumonia-associated hospitalizations in English children, April 1995–March 1998. Epidemiol Infect. 2002;129(1):99–106.PubMed CentralPubMedGoogle Scholar
  37. Escobar GJ, Ragins A, Li SX, Prager L, Masaquel AS, Kipnis P. Recurrent wheezing in the third year of life among children born at 32 weeks’ gestation or later: relationship to laboratory-confirmed, medically attended infection with respiratory syncytial virus during the first year of life. Arch Pediatr Adolesc Med. 2010;164(10):915–22.PubMedView ArticleGoogle Scholar
  38. Chan KN, Noble Jamieson CM, Elliman A, Bryan EM, Silverman M. Lung function in children of low birth weight. Arch Dis Child. 1989;64:1284–9.PubMed CentralPubMedView ArticleGoogle Scholar
  39. Henderson J, Hilliard TN, Sherriff A, Stalker D, Al SN, Thomas HM. Hospitalization for RSV bronchiolitis before 12 months of age and subsequent asthma, atopy and wheeze: a longitudinal birth cohort study. Pediatr Allergy Immunol. 2005;16:386–92.PubMedView ArticleGoogle Scholar
  40. Bacharier LB, Cohen R, Schweiger T, Yin-Declue H, Christie C, Zheng J, et al. Determinants of asthma after severerespiratory syncytial virus bronchiolitis. J Allergy Clin Immunol. 2012;130:91–100.PubMed CentralPubMedView ArticleGoogle Scholar
  41. Stein RT, Sherrill D, Morgan WJ, Holberg CJ, Halonen M, Taussig LM, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet. 1999;354:541–5.PubMedView ArticleGoogle Scholar
  42. Sigurs N, Aljassim F, Kjellman B, Robinson PD, Sigurbergsson F, Bjarnason R, et al. Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. Thorax. 2010;65:1045–52.PubMedView ArticleGoogle Scholar
  43. Mai XM, Gaddlin PO, Nilsson L, Finnstrom O, Bjorksten B, Jenmalm MC. Asthma, lung function and allergy in 12-year-old children with very low birth weight: a prospective study. Pediatr Allergy Immunol. 2003;14:184–92.PubMedView ArticleGoogle Scholar
  44. Blanken MO, Rovers MM, Molenaar JM, Winkler-Seinstra PL, Meijer A, Kimpen JL, et al. Dutch RSV Neonatal Network. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med. 2013;368(19):1791–9.PubMedView ArticleGoogle Scholar

Copyright

© Lanari et al.; licensee BioMed Central. 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement